Sonnet BioTherapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Disclosures About Fair Value - Schedule of Fair Value of Measured Assets and Liabilities (Details)

Disclosures About Fair Value - Schedule of Fair Value of Measured Assets and Liabilities (Details) (USD $)	Mar. 31, 2015	Jan. 31, 2015	Dec. 31, 2014
Fair Value Disclosure [Line Items]
Available-for-sale securities	$ 35,362hotr_InvestmentsFairValue		$ 35,362hotr_InvestmentsFairValue
Embedded conversion feature	1,767,300us-gaap_DerivativeLiabilities	125,089us-gaap_DerivativeLiabilities	1,610,900us-gaap_DerivativeLiabilities
Warrants	312,747us-gaap_WarrantsAndRightsOutstanding		334,300us-gaap_WarrantsAndRightsOutstanding
Quoted Prices In Active Markets Of Identical Assets (Level 1) [Member]
Fair Value Disclosure [Line Items]
Available-for-sale securities	35,362		35,362
Embedded conversion feature
Warrants
Significant Other Observable Inputs (Level 2) [Member]
Fair Value Disclosure [Line Items]
Available-for-sale securities
Embedded conversion feature
Warrants
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Disclosure [Line Items]
Available-for-sale securities	35,362		35,362
Embedded conversion feature	1,767,300		1,610,900
Warrants	$ 312,747		$ 334,300

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

+ References + Details